Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1998;7(3):149–152. doi: 10.1080/09629359891063

Immunotherapy of Crohn's disease.

C van Montfrans 1, L Camoglio 1, S J van Deventer 1
PMCID: PMC1781847  PMID: 9705600

Abstract

Although the initiating events of Crohn's disease are unknown, models of experimental colitis have provided new insights in the immunologically mediated pathways of mucosal inflammation. In Crohn's disease activated mucosal T lymphocytes produce proinflammatory cytokines within the mucosal compartment. With this understanding, there has been a shift in past years from the use of unspecific anti-inflammatory agents (corticosteroids, aminosalicylates) to the use of immunomodulatory drugs (azathioprine, methotrexate). Moreover, novel strategies have been designed for specific targets in Crohn's disease, in particular T lymphocytes and cytokines. In an open label study treatment of steroid-refractory Crohn's disease with anti- CD4+ antibodies was well tolerated and showed clinical benefit. However, a sustained depletion of the CD4+ cells precluded further clinical trials. In controlled clinical studies, anti-tumour necrosis factor (TNF-alpha) antibodies induced complete remissions and few side effects were observed. One study suggested efficacy in active Crohn's disease of recombinant interleukin-10. Long term treatment studies will have to answer questions about the indications for use, benefit and toxicity. Altogether, these results hold promise for future management of Crohn's disease, where disease-modifying interventions and strategies that effectively maintain disease remission will play a key role.

Full Text

The Full Text of this article is available as a PDF (135.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauditz J., Haemling J., Ortner M., Lochs H., Raedler A., Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut. 1997 Apr;40(4):470–474. doi: 10.1136/gut.40.4.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berg D. J., Davidson N., Kühn R., Müller W., Menon S., Holland G., Thompson-Snipes L., Leach M. W., Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996 Aug 15;98(4):1010–1020. doi: 10.1172/JCI118861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Briskin M., Winsor-Hines D., Shyjan A., Cochran N., Bloom S., Wilson J., McEvoy L. M., Butcher E. C., Kassam N., Mackay C. R. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997 Jul;151(1):97–110. [PMC free article] [PubMed] [Google Scholar]
  4. Elson C. O., Sartor R. B., Tennyson G. S., Riddell R. H. Experimental models of inflammatory bowel disease. Gastroenterology. 1995 Oct;109(4):1344–1367. doi: 10.1016/0016-5085(95)90599-5. [DOI] [PubMed] [Google Scholar]
  5. Evans R. C., Clarke L., Heath P., Stephens S., Morris A. I., Rhodes J. M. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther. 1997 Dec;11(6):1031–1035. doi: 10.1046/j.1365-2036.1997.00251.x. [DOI] [PubMed] [Google Scholar]
  6. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991 Dec 1;147(11):3815–3822. [PubMed] [Google Scholar]
  7. Fiorentino D. F., Zlotnik A., Vieira P., Mosmann T. R., Howard M., Moore K. W., O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991 May 15;146(10):3444–3451. [PubMed] [Google Scholar]
  8. Fuss I. J., Neurath M., Boirivant M., Klein J. S., de la Motte C., Strong S. A., Fiocchi C., Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996 Aug 1;157(3):1261–1270. [PubMed] [Google Scholar]
  9. Hogaboam C. M., Vallance B. A., Kumar A., Addison C. L., Graham F. L., Gauldie J., Collins S. M. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest. 1997 Dec 1;100(11):2766–2776. doi: 10.1172/JCI119823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Howard M., O'Garra A., Ishida H., de Waal Malefyt R., de Vries J. Biological properties of interleukin 10. J Clin Immunol. 1992 Jul;12(4):239–247. doi: 10.1007/BF00918147. [DOI] [PubMed] [Google Scholar]
  11. Leach M. W., Bean A. G., Mauze S., Coffman R. L., Powrie F. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol. 1996 May;148(5):1503–1515. [PMC free article] [PubMed] [Google Scholar]
  12. McDonald S. A., Palmen M. J., Van Rees E. P., MacDonald T. T. Characterization of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis. Immunology. 1997 May;91(1):73–80. doi: 10.1046/j.1365-2567.1997.00217.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Meenan J., Spaans J., Grool T. A., Pals S. T., Tytgat G. N., van Deventer S. J. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut. 1997 Feb;40(2):241–246. doi: 10.1136/gut.40.2.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Moreland L. W., Baumgartner S. W., Schiff M. H., Tindall E. A., Fleischmann R. M., Weaver A. L., Ettlinger R. E., Cohen S., Koopman W. J., Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–147. doi: 10.1056/NEJM199707173370301. [DOI] [PubMed] [Google Scholar]
  15. Mullin G. E., Lazenby A. J., Harris M. L., Bayless T. M., James S. P. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology. 1992 May;102(5):1620–1627. doi: 10.1016/0016-5085(92)91722-g. [DOI] [PubMed] [Google Scholar]
  16. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994 Mar;35(3):360–362. doi: 10.1136/gut.35.3.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Murch S. H., Braegger C. P., Walker-Smith J. A., MacDonald T. T. Distribution and density of TNF immunoreactivity in chronic inflammatory bowel disease. Adv Exp Med Biol. 1995;371B:1327–1330. [PubMed] [Google Scholar]
  18. Neurath M. F., Fuss I., Kelsall B. L., Stüber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995 Nov 1;182(5):1281–1290. doi: 10.1084/jem.182.5.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Neurath M. F., Fuss I., Pasparakis M., Alexopoulou L., Haralambous S., Meyer zum Büschenfelde K. H., Strober W., Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997 Jul;27(7):1743–1750. doi: 10.1002/eji.1830270722. [DOI] [PubMed] [Google Scholar]
  20. Neurath M. F., Pettersson S., Meyer zum Büschenfelde K. H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996 Sep;2(9):998–1004. doi: 10.1038/nm0996-998. [DOI] [PubMed] [Google Scholar]
  21. Pan M. G., Xiong J., Copeland N. G., Gilbert D. J., Jenkins N. A., Goeddel D. V. Sequence, genomic organization, and chromosome localization of the mouse TRADD gene. J Inflamm. 1995;46(3):168–175. [PubMed] [Google Scholar]
  22. Podolsky D. K., Lobb R., King N., Benjamin C. D., Pepinsky B., Sehgal P., deBeaumont M. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest. 1993 Jul;92(1):372–380. doi: 10.1172/JCI116575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Powrie F., Coffman R. L., Correa-Oliveira R. Transfer of CD4+ T cells to C.B-17 SCID mice: a model to study Th1 and Th2 cell differentiation and regulation in vivo. Res Immunol. 1994 Jun;145(5):347–353. doi: 10.1016/s0923-2494(94)80198-3. [DOI] [PubMed] [Google Scholar]
  24. Powrie F., Correa-Oliveira R., Mauze S., Coffman R. L. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med. 1994 Feb 1;179(2):589–600. doi: 10.1084/jem.179.2.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Powrie F., Leach M. W. Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. Ther Immunol. 1995 Apr;2(2):115–123. [PubMed] [Google Scholar]
  26. Powrie F., Leach M. W., Mauze S., Menon S., Caddle L. B., Coffman R. L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994 Oct;1(7):553–562. doi: 10.1016/1074-7613(94)90045-0. [DOI] [PubMed] [Google Scholar]
  27. Reimund J. M., Wittersheim C., Dumont S., Muller C. D., Baumann R., Poindron P., Duclos B. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol. 1996 May;16(3):144–150. doi: 10.1007/BF01540912. [DOI] [PubMed] [Google Scholar]
  28. Sandborn W. J. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996 Mar;91(3):423–433. [PubMed] [Google Scholar]
  29. Sartor R. B. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994 Feb;106(2):533–539. doi: 10.1016/0016-5085(94)90614-9. [DOI] [PubMed] [Google Scholar]
  30. Scallon B. J., Moore M. A., Trinh H., Knight D. M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995 Apr;7(3):251–259. doi: 10.1006/cyto.1995.0029. [DOI] [PubMed] [Google Scholar]
  31. Simpson S. J., Mizoguchi E., Allen D., Bhan A. K., Terhorst C. Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol. 1995 Sep;25(9):2618–2625. doi: 10.1002/eji.1830250932. [DOI] [PubMed] [Google Scholar]
  32. Stack W. A., Mann S. D., Roy A. J., Heath P., Sopwith M., Freeman J., Holmes G., Long R., Forbes A., Kamm M. A. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997 Feb 22;349(9051):521–524. doi: 10.1016/s0140-6736(97)80083-9. [DOI] [PubMed] [Google Scholar]
  33. Stronkhorst A., Radema S., Yong S. L., Bijl H., ten Berge I. J., Tytgat G. N., van Deventer S. J. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut. 1997 Mar;40(3):320–327. doi: 10.1136/gut.40.3.320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Summers R. W., Switz D. M., Sessions J. T., Jr, Becktel J. M., Best W. R., Kern F., Jr, Singleton J. W. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979 Oct;77(4 Pt 2):847–869. [PubMed] [Google Scholar]
  35. Targan S. R., Hanauer S. B., van Deventer S. J., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 9;337(15):1029–1035. doi: 10.1056/NEJM199710093371502. [DOI] [PubMed] [Google Scholar]
  36. Van Deventer S. J. Tumour necrosis factor and Crohn's disease. Gut. 1997 Apr;40(4):443–448. doi: 10.1136/gut.40.4.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Williams L. M., Gibbons D. L., Gearing A., Maini R. N., Feldmann M., Brennan F. M. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest. 1996 Jun 15;97(12):2833–2841. doi: 10.1172/JCI118739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Yacyshyn B. R., Lazarovits A., Tsai V., Matejko K. Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns. Gastroenterology. 1994 Nov;107(5):1364–1371. doi: 10.1016/0016-5085(94)90538-x. [DOI] [PubMed] [Google Scholar]
  39. van Deventer S. J., Elson C. O., Fedorak R. N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997 Aug;113(2):383–389. doi: 10.1053/gast.1997.v113.pm9247454. [DOI] [PubMed] [Google Scholar]
  40. van Dullemen H. M., van Deventer S. J., Hommes D. W., Bijl H. A., Jansen J., Tytgat G. N., Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995 Jul;109(1):129–135. doi: 10.1016/0016-5085(95)90277-5. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES